Icahn scores a fortune on two big biotech plays

Carl Icahn may be the last person you'd want to see knocking on your biotech's front door, but investors who went along on his joyride at Biogen Idec and Genzyme have profited handsomely. Boston Globe columnist Steve Syre did the math and concluded that Icahn earned $614 million on his investment in Biogen and $237 million more on Genzyme. Altogether, that's a gain of $851 million. Says Syre: Executives don't like his rough tactics, but no one can argue about the results. Column

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.